A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating
agent comprising at least one substance selected from the group consisting of osteoclastogenesis
inhibitory factor (OCIF), its homologs, and its variants, and a polysaccharide
or its derivatives. As the polysaccharide or its derivatives, heparin, dextran
sulfate and the like can be used. A bone-pathobolism treating agent is provided
which has excellent therapeutic effect on bone-pathobolism such as osteoporosis,
hypercalcemia, or chronic articular rheumatism and persistance of the activity.
The agent is useful as a medicine.
